| 靶点: |
IC50: 120 nM (Ces3), 100 nM (Ces1f). |
| 体内研究: |
WWL113 (30 mg/kg, orally once a day) results in major improvement of multiple features of metabolic syndrome and ameliorated obesity-diabetes in mice with lowered levels of nonesterified free fatty acids (NEFAs), triglycerides (TGs), total cholesterol and fasted glucose as well as enhanced glucose tolerance. WWL113 ameliorates obesity-diabetes in mice. |
| 参考文献: |
1. Dominguez, E., Galmozzi, A., Chang, J.W., et al. Integrated phenotypic and activity-based profiling links Ces3 to obesity and diabetes. Nat. Chem. Biol. 10(2), 113-121 (2014). 2. Galmozzi, et al. ThermoMouse: an in vivo model to identify modulators of UCP1 expression in brown adipose tissue. Cell Rep. 2014 Dec 11;9(5):1584-1593. 3. Turcotte C, et al. The Endocannabinoid Metabolite Prostaglandin E2 (PGE2)-Glycerol Inhibits Human Neutrophil Functions: Involvement of Its Hydrolysis into PGE2 and EP Receptors. J Immunol. 2017 Apr 15;198(8):3255-3263. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.143 ml |
10.717 ml |
21.435 ml |
| 5 mM |
0.429 ml |
2.143 ml |
4.287 ml |
| 10 mM |
0.214 ml |
1.072 ml |
2.143 ml |
| 50 mM |
0.043 ml |
0.214 ml |
0.429 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |